Apoptosis is a form of programmed cell death that is regulated by the balance between
prosurvival and proapoptotic BCL-2 protein family members. Evasion of apoptosis is a …

For over three decades, a mainstay and goal of clinical oncology has been the development
of therapies promoting the effective elimination of cancer cells by apoptosis. This …

Targeting the interaction between tumor suppressor p53 and the E3 ligase MDM2
represents an attractive treatment approach for cancers with wild-type or functional TP53 …

The BCL2 inhibitor venetoclax induces high rates of durable remission in patients with
previously treated chronic lymphocytic leukemia (CLL). However, despite continuous daily …

Ibrutinib, obinutuzumab, and venetoclax demonstrate synergy in preclinical models of
mantle cell lymphoma (MCL). OAsIs (NCT02558816), a single-arm multicenter prospective …

Although lymphoma is a very heterogeneous group of biologically complex malignancies,
tumor cells across all B cell lymphoma subtypes share a set of underlying traits that promote …

Chronic lymphocytic leukemia (CLL) cells cycle between lymph node (LN) and peripheral
blood (PB) and display major shifts in Bcl-2 family members between those compartments …

Bromodomain extraterminal protein (BETP) inhibitors transcriptionally repress oncoproteins
and nuclear factor-κB (NF-κB) target genes that undermines the growth and survival of …

The ability to inhibit mitochondrial apoptosis is a hallmark of B-cell non-Hodgkin lymphomas
(B-NHL). Activation of mitochondrial apoptosis is tightly controlled by members of B-cell …

A hallmark of cancer is cell death evasion, underlying suboptimal responses to
chemotherapy, targeted agents, and immunotherapies. The approval of the antiapoptotic …